生物标记市场规模、份额及成长分析（按产品、类型、研究领域、技术、适应症、应用、最终用户和地区）－2025 年至 2032 年产业预测

预计生物标记市场规模将在 2023 年达到 582 亿美元，从 2024 年的 660.6 亿美元增长到 2032 年的 1819.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 13.5%。

生物标记市场正在经历强劲成长，主要原因是慢性病的增加、技术进步以及个人化医疗需求的增加。随着全球患者数量的增加，使用生物标记进行有效的早期检测、监测和诊断的需求也日益增加。蛋白质体学、基因组学和代谢体学技术的创新正在加速新物标记的发现，进一步推动市场扩张。然而，开发和检验生物标誌物的成本高昂以及公众对其益处的认识有限等挑战可能会阻碍其发展。儘管存在这些障碍，个体化医疗和持续的技术进步仍然带来了大量机会，使生物标记市场具备了开发和投资的条件。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 宏观经济指标
• 价值链分析
• 定价分析
• 专利分析
• 监管分析
• 技术分析
• 案例研究
• 客户和购买标准分析

按产品/服务分類的生物标誌市场规模

• 市场概览
• 耗材
  • 检测试剂套件
  • 试剂和化学品
  • 列和过滤器
• 服务
• 软体

生物标誌物市场规模（按类型）

• 市场概览
• 安全生物标记
• 疗效生物标记
  • 预测性生物标记
  • 替代生物标记
  • 动态物标誌物
  • 预测性生物标记
• 检验生物标记

按研究领域分類的生物标记市场规模

• 市场概览
• 基因组学
• 蛋白质体学
• 代谢体学
• 其他研究领域

生物标誌物市场规模（按技术划分）

• 市场概览
• 免疫检测
  • ELISA
  • 蛋白质微阵列
  • 蛋白质印迹法
• NGS
• PCR
• 质谱法
• 层析法
• 其他技术

生物标记市场规模（依适应症划分）

• 市场概览
• 癌症
• 感染疾病
• 免疫系统疾病
• 神经系统疾病
• 心血管疾病
• 其他疾病适应症

生物标誌物市场规模（按应用）

• 市场概览
• 临床诊断
• 药物研发
• 个人化医疗
• 临床研究
• 其他用途

生物标誌物市场规模（按最终用户划分）

• 市场概览
• 製药和生物技术公司
• 医院和诊断实验室
• 学术研究所
• 其他最终用户

生物标誌市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Hoffmann-La Roche AG（Switzerland）
• Thermo Fisher Scientific Inc.（United States）
• Agilent Technologies, Inc.（United States）
• QIAGEN NV（Netherlands）
• Bio-Rad Laboratories, Inc.（United States）
• Merck & Co., Inc.（United States）
• PerkinElmer, Inc.（United States）
• Illumina, Inc.（United States）
• BD（Becton, Dickinson and Company）（United States）
• Myriad Genetics, Inc.（United States）
• Siemens Healthineers AG（Germany）
• Danaher Corporation（United States）
• Biomerieux SA（France）
• Waters Corporation（United States）
• Abbott Laboratories（United States）
• Sysmex Corporation（Japan）
• Bio-Techne Corporation（United States）
• Charles River Laboratories International, Inc.（United States）
• Eurofins Scientific SE（Luxembourg）

结论和建议

Biomarkers Market size was valued at USD 58.2 billion in 2023 and is poised to grow from USD 66.06 billion in 2024 to USD 181.92 billion by 2032, growing at a CAGR of 13.5% during the forecast period (2025-2032).

The biomarkers market is experiencing robust growth, primarily fueled by the increasing prevalence of chronic diseases, advancements in technology, and a growing demand for personalized medicine. As global patient numbers rise, the need for effective early detection, monitoring, and diagnosis through biomarkers is intensifying. Innovations in proteomic, genomic, and metabolomics technologies are facilitating the discovery of new biomarkers, further propelling market expansion. However, challenges such as high costs associated with biomarker development and validation, as well as limited public awareness regarding their benefits, may hinder growth. Despite these obstacles, opportunities abound in the form of tailored medicine and continued technological advancements, making the biomarkers market ripe for development and investment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biomarkers Market Segments Analysis

Global Biomarkers Market is segmented by Product, Type, Research Area, Technology, Disease Indication, Application, End User and region. Based on Product, the market is segmented into Consumables, Services and Software. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Research Area, the market is segmented into Genomics, Proteomics, Metabolomics and Other Research Areas. Based on Technology, the market is segmented into Immunoassays, NGS, PCR, Mass Spectrometry,Chromatographyand Other Technologies. Based on Disease Indication, the market is segmented into Cancer, Infectious Diseases, Immunological Disorders, Neurological Disorders, Cardiovascular Disorders and Other Disease Indications. Based on Application, the market is segmented into Clinical Diagnostics, Drug Discovery & Development, Personalized Medicine, Clinical Research and Other Applications. Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Academic & Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biomarkers Market

The demand for biomarkers is rapidly increasing as healthcare shifts towards more personalized treatment approaches that consider the unique needs and genetic profiles of patients. This trend underscores the pivotal role of biomarkers in improving therapeutic outcomes. In recent years, the growth has been propelled by advanced research initiatives in biotechnology and molecular biology, which are facilitating the identification and application of novel biomarkers across various medical fields. As a result, there is a burgeoning interest in leveraging these biological indicators to tailor medical treatments, ultimately enhancing patient care and driving further innovation in the biomarkers market.

Restraints in the Biomarkers Market

The biomarkers market faces several significant challenges that could hinder its growth. Variability in biomarker testing methodologies and a lack of standardized practices across platforms can lead to inconsistent results, deterring widespread adoption. Additionally, the validation process for biomarkers associated with specific conditions and diseases often proves to be complex and time-consuming, further impeding progress. These hurdles not only slow the overall development of new biomarker technologies but also potentially restrict the market's expansion, as stakeholders may be hesitant to invest in uncertain outcomes or prolonged timelines for validation efforts.

Market Trends of the Biomarkers Market

The biomarker market is witnessing a significant trend towards the increased utilization of vitality biomarkers, which empower healthcare providers to assess patients' health proactively, even before symptoms manifest. This shift towards early intervention is crucial in averting the progression of various health conditions, thus enhancing patient outcomes. The integration of IoT devices and wearables into healthcare is further amplifying this trend, as these technologies enable continuous monitoring of vital health metrics in real-time. The resulting rich datasets not only facilitate personalized treatment plans but also bolster the quality of diagnostics, paving the way for innovative solutions in preventive medicine and chronic disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies
• Customer And Buying Criteria Analysis

Global Biomarkers Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Consumables
  • Assay Kits
  • Reagents & Chemicals
  • Columns & Filters
• Services
• Software

Global Biomarkers Market Size by Type & CAGR (2025-2032)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
  • Predictive Biomarkers
  • Surrogate Biomarkers
  • Pharmacodynamic Biomarkers
  • Prognostic Biomarkers
• Validation Biomarkers

Global Biomarkers Market Size by Research Area & CAGR (2025-2032)

• Market Overview
• Genomics
• Proteomics
• Metabolomics
• Other Research Areas

Global Biomarkers Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Immunoassays
  • ELISA
  • Protein Microarrays
  • Western Blot
• NGS
• PCR
• Mass Spectrometry
• Chromatography
• Other Technologies

Global Biomarkers Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Infectious Diseases
• Immunological Disorders
• Neurological Disorders
• Cardiovascular Disorders
• Other Disease Indications

Global Biomarkers Market Size by Application & CAGR (2025-2032)

• Market Overview
• Clinical Diagnostics
• Drug Discovery & Development
• Personalized Medicine
• Clinical Research
• Other Applications

Global Biomarkers Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Other End Users

Global Biomarkers Market Size & CAGR (2025-2032)

• North America (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • US
  • Canada
• Europe (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Type, Research Area, Technology, Disease Indication, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BD (Becton, Dickinson and Company) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations